Experimental study of intraperitoneal chemotherapy with mitomycin C bound to carbon nanopaticles

ZHANG Li,Xiaona Wang,DING Xue-wei,PAN Yuan,LIANG Han
DOI: https://doi.org/10.3969/j.issn.1673-5269.2008.07.006
2008-01-01
Abstract:OBJECTIVE: To analyze the pharmacokinetics of intraperitoneal chemotherapy with MMC bound to carbon nanoparticles. METHODS: A nude mouse model with transplanted human gastric cancer was established. The mice were given MMC by iv or intraperitoneal (ip)injections, or given ip MMC bound to carbon nanopaticles (MMC-CNP). Pharmacokinetic assays were carried out at different time points, to measure the MMC concentrations by HPLC and the results were compared. RESULTS: The MMC concentration in lymph nodes, mesentery and peritoneal exudate of MMC-CNP group was significantly higher than that of MMC solution ip group and MMC iv group, P<0.01. On the other hand, the MMC level in plasma was significantly lower than that in the two control groups, P<0.01. High MMC level was maintained at least 24 hours in the MMC-CNP group. Intraperitoneal chemotherapy with MMC solution resulted in a low MMC concentration in the mesentery and lymph nodes, and only a transient high level of MMC in peritoneal exudate, P<0.01. After iv administration, a significantly higher level of MMC concentration occurred in the plasma, but only a shortly increased concentration of MMC in the mesentery, and lower concentration in peritoneal exudate and lymph nodes as compared with those in the other two groups, P<0.01. CONCLUSION: Carbon nanoparticles is a perfect drug delivery system for lymphatic targeting in preventing metastasis and recurrence of advanced gastric cancer.
What problem does this paper attempt to address?